Abstract:BackgroundTargeting ubiquitin-dependent proteolysis is one of the strategies in cancer therapy. CRLCDT2 and CRLDDB2 are two key E3 ubiquitin ligases involved in DNA replication and DNA damage repair. But CDT2 and DDB2 are opposite prognostic factors in kinds of cancers, and the underlining mechanism needs to be elucidated.MethodsSmall interfering RNAs were used to determine the function of target genes. Co-immunoprecipitation (Co-IP) was performed to detect the interaction between DDB2 and CDT2. Immunofluorescence assays and fluorescence activating cell sorting (FACS) were used to measure the change of DNA content. In vivo ubiquitination assay was carried out to clarify the ubiquitination of CDT2 mediated by DDB2. Cell synchronization was performed to arrest cells at G1/S and S phase. The mechanism involved in DDB2-mediated CDT2 degradation was investigated by constructing plasmids with mutant variants and measured by Western blot. Immunohistochemistry was performed to determine the relationship between DDB2 and CDT2. Paired two-side Student's t-test was used to measure the significance of the difference between control group and experimental group.ResultsKnockdown of DDB2 stabilized CDT2, while over-expression of DDB2 enhanced ubiquitination of CDT2, and subsequentially degradation of CDT2. Although both DDB2 and CDT2 contain PIP (PCNA-interacting protein) box, PIP box is dispensable for DDB2-mediated CDT2 degradation. Knockdown of PCNA had negligible effects on the stability of CDT2, but promoted accumulation of CDT1, p21 and SET8. Silencing of DDB2 arrested cell cycle in G1 phase, destabilized CDT1 and reduced the chromatin loading of MCMs, thereby blocked the formation of polyploidy induced by ablation of CDT2. In breast cancer and ovarian teratoma tissues, high level of DDB2 was along with lower level of CDT2.ConclusionsWe found that CRL4(DDB2) is the novel E3 ubiquitin ligases of CDT2, and DDB2 regulates DNA replication through indirectly regulates CDT1 protein stability by degrading CDT2 and promotes the assembly of pre-replication complex. Our results broaden the horizon for understanding the opposite function of CDT2 and DDB2 in tumorigenesis, and may provide clues for drug discovery in cancer therapy.

L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes.

L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage.

CRL4ADTL Degrades DNA-PKcs to Modulate NHEJ Repair and Induce Genomic Instability and Subsequent Malignant Transformation

DDB2 Regulates DNA Replication Through PCNA-independent Degradation of CDT2

PDCD5 Interacts with P53 and Functions As a Positive Regulator in the P53 Pathway.

CUL4–DDB1 Ubiquitin Ligase Interacts with Multiple WD40-repeat Proteins and Regulates Histone Methylation

XPC promotes MDM2-mediated degradation of the p53 tumor suppressor.

Proliferating Cell Nuclear Antigen Interacts with the CRL4 Ubiquitin Ligase Subunit CDT2 in DNA Synthesis–induced Degradation of CDT1

Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27(Kip1) and cyclin E degradation

DNA damage-induced activation of CUL4B targets HUWE1 for proteasomal degradation.

Regulation of MDM2 Stability After DNA Damage

Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.

DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites

A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

CRL4B catalyzes H2AK119 monoubiquitination and coordinates with PRC2 to promote tumorigenesis.

SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes.

P300/mdm2 Complexes Participate in MDM2-mediated P53 Degradation.

DTL Promotes Cancer Progression by PDCD4 Ubiquitin-Dependent Degradation

Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase

Autoactivation of the MDM2 E3 Ligase by Intramolecular Interaction

Interplay Between MDM2, MDMX, Pirh2 and COP1: the Negative Regulators of P53